4.7 Article

Color Fluorescence Ratio for Detection of Bronchial Dysplasia and Carcinoma In situ

Journal

CLINICAL CANCER RESEARCH
Volume 15, Issue 14, Pages 4700-4705

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-08-1644

Keywords

-

Categories

Funding

  1. NCI NIH HHS [P50 CA070907, P50 CA070907-03S29001, U01 CA084971, U01 CA084971-09] Funding Source: Medline

Ask authors/readers for more resources

Background: Autofluorescence bronchoscopy is more sensitive than conventional bronchoscopy for detecting early airway mucosal lesions. Decreased specificity can lead to excessive biopsy and increased procedural time. Onco-LIFE, a device that combines fluorescence and reflectance imaging, allows numeric representation by expressing red-to-green ratio (R/G ratio) within the region of interest. The aim of the study was to determine if color fluorescence ratio (R/G ratio) added to autofluorescence bronchoscopy could provide an objective means to guide biopsy. Methods: Subjects at risk for lung cancer were recruited at two centers: VU University Medical Centre (Amsterdam) and BC Cancer Agency (Canada). R/G ratio for each site appearing normal or abnormal was measured before biopsy. R/G ratios were correlated with pathology, and a receiver operating characteristic curve of R/G ratio for high-grade and moderate dysplasia was done. Following analysis of the training data set obtained from two centers, a prospective validation study was done. Results: Three thousand three hundred sixty-two adequate biopsies from 738 subjects with their corresponding R/G ratios were analyzed. R/G ratio 0.54 conferred 85% sensitivity and 80% specificity for the detection of high-grade and moderate dysplasia, area under the curve was 0.90, and 95% confidence interval was 0.88 to 0.92. In another 70 different sites that were assessed, kappa measurements of agreement of R/G ratios with visual scores and pathology were 0.66 (P < 0.0001) and 0.61 (P < 0.0001), respectively. R/G ratio combined with visual score improved specificity to 88% (95% confidence interval, 0.73-0.96) for high-grade and moderate dysplasia. Conclusion: Color fluorescence ratio can objectively guide the bronchoscopist in selecting sites for biopsy with good pathologic correlation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

Intestinal hypomotility in systemic sclerosis: a histological study into the sequence of events

M. den Braber-Ymker, M. C. Vonk, K. Grunberg, M. Lammens, I. D. Nagtegaal

Summary: The histological evaluation of intestinal involvement in systemic sclerosis (SSc) revealed differences in vascular changes, muscle layer fibrosis, and neuronal reduction between SSc patients and controls. The diversity among patients suggests parallel pathological processes, explaining the variety of histological features and clinical symptoms observed in SSc.

CLINICAL RHEUMATOLOGY (2021)

Article Pathology

IMI-Bigpicture: A Central Repository for Digital Pathology

Pierre Moulin, Katrien Grunberg, Erio Barale-Thomas, Jeroen van der Laak

Summary: The goal of the project is to drive digital transformation in pathology by establishing a whole slide imaging platform, connecting pathologists, researchers, AI developers, patients, and industry participants, with an emphasis on sustainable development and reciprocal cooperation.

TOXICOLOGIC PATHOLOGY (2021)

Article Oncology

Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice

Elisabeth M. P. Steeghs, Hans Gelderblom, Vincent K. Y. Ho, Quirinus J. M. Voorham, Stefan M. Willems, Katrien Grunberg, Marjolijn J. L. Ligtenberg

Summary: The study found that in the Netherlands, predictive mutation analysis is mainly conducted in high-risk or metastatic GIST patients, with a higher testing rate in patients treated at expertise centers. However, not all patients who have received imatinib therapy have received mutation-tailored treatment according to the guidelines.

GASTRIC CANCER (2021)

Article Health Care Sciences & Services

Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing

Clemence T. B. Pasmans, Bastiaan B. J. Tops, Elisabeth M. P. Steeghs, Veerle M. H. Coupe, Katrien Grunberg, Eiko K. de Jong, Ed M. D. Schuuring, Stefan M. Willems, Marjolijn J. l. Ligtenberg, Valesca P. Retel, Hans van Snellenberg, Ewart de Bruijn, Edwin Cuppen, Geert W. J. Frederix

Summary: This study calculated and compared the total cost of current diagnostic techniques and WGS in the treatment of NSCLC, melanoma, CRC, and GIST in the Netherlands. The results showed that operational costs accounted for over 90% of the total cost per technique, with variations ranging from euro 58 to euro 2925 per cancer patient. Detailed cost differences and value comparisons between these diagnostic techniques enable future economic evaluations to support decision-making.

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2021)

Article Oncology

Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer

Peter H. J. Slootbeek, Iris S. H. Kloots, Minke Smits, Inge M. van Oort, Winald R. Gerritsen, Jack A. Schalken, Marjolijn J. L. Ligtenberg, Katrien Grunberg, Leonie Kroeze, Haiko J. Bloemendal, Niven Mehra

Summary: The study found that almost half of advanced prostate cancer patients receive recommendations for genetically matched therapies, with over 40% of them showing durable responses to the treatment. These findings support the routine referral of selected prostate cancer patients to molecular tumour boards.

BRITISH JOURNAL OF CANCER (2022)

Article Cell & Tissue Engineering

SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids

Jitske Jansen, Katharina C. Reimer, James S. Nagai, Finny S. Varghese, Gijs J. Overheul, Marit de Beer, Rona Roverts, Deniz Daviran, Liline A. S. Fermin, Brigith Willemsen, Marcel Beukenboom, Sonja Djudjaj, Saskia von Stillfried, Larissa E. van Eijk, Mirjam Mastik, Marian Bulthuis, Wilfred den Dunnen, Harry van Goor, Jan-Luuk Hillebrands, Sergio H. Triana, Theodore Alexandrov, Marie-Cherelle Timm, Bartholomeus T. van den Berge, Martijn van den Broek, Quincy Nlandu, Joelle Heijnert, Eric M. J. Bindels, Remco M. Hoogenboezem, Fieke Mooren, Christoph Kuppe, Pascal Miesen, Katrien Grunberg, Ties Ijzermans, Eric J. Steenbergen, Jan Czogalla, Michiel F. Schreuder, Nico Sommerdijk, Anat Akiva, Peter Boor, Victor G. Puelles, Juergen Floege, Tobias B. Huber, Ronald P. van Rij, Ivan G. Costa, Rebekka K. Schneider, Bart Smeets, Rafael Kramann

Summary: The study found that SARS-CoV-2 can directly infect kidney cells, leading to cell injury and fibrosis, causing kidney failure. Inhibitors can alleviate the infection.

CELL STEM CELL (2022)

Article Pathology

Nationwide evaluation of mutation-tailored anti-EGFR therapy selection in patients with colorectal cancer in daily clinical practice

Elisabeth M. P. Steeghs, Geraldine R. Vink, Marloes A. G. Elferink, Quirinus J. M. Voorham, Hans Gelderblom, Iris D. Nagtegaal, Katrien Grunberg, Marjolijn J. L. Ligtenberg

Summary: The study in the Netherlands showed an increase in mutation testing rates for CRC patients over time, with anti-EGFR therapy mainly used in KRAS/NRAS wild-type patients after the third treatment line. The national average mutation rate was 63.9%, and NGS-based approaches detected more potential biomarkers.

JOURNAL OF CLINICAL PATHOLOGY (2022)

Correction Oncology

Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer (vol 126, pg 907, 2022)

Peter H. J. Slootbeek, Iris S. H. Kloots, Minke Smits, Inge M. van Oort, Winald R. Gerritsen, Jack A. Schalken, Marjolijn J. L. Ligtenberg, Katrien Grunberg, Leonie I. Kroeze, Haiko J. Bloemendal, Niven Mehra

BRITISH JOURNAL OF CANCER (2022)

Article Oncology

Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice

Elisabeth M. P. Steeghs, Harry J. M. Groen, Ed Schuuring, Mieke J. Aarts, Ronald A. M. Damhuis, Quirinus J. M. Voorham, Path Consortium, Marjolijn J. L. Ligtenberg, Katrien Grunberg

Summary: This study evaluated molecular testing and treatment selection in stage IV NSCLC patients in the Netherlands. The results showed that predictive molecular testing rates were highest for adenocarcinomas and lowest for squamous cell carcinomas. Next-generation sequencing (NGS) approaches had a higher detection rate of therapeutic alterations compared to non-NGS approaches.

LUNG CANCER (2022)

Review Cell Biology

Systematic review and meta-analysis of the prognostic impact of lymph node micrometastasis and isolated tumour cells in patients with stage I-IIIA non-small cell lung cancer

Melek Huyuk, Marta Fiocco, Pieter E. Postmus, Danielle Cohen, Jan H. von der Thusen

Summary: This systematic review and meta-analysis investigated the association between lymph node micrometastases in stage I-IIIA NSCLC patients and overall survival (OS) and disease-free survival (DFS) after surgical resection. The study found that patients with lymph node micrometastases detected through ancillary techniques had significantly poorer OS and DFS compared to patients without micrometastases. The 5-year OS and DFS rates were lower in the micrometastasis group compared to the no micrometastasis group.

HISTOPATHOLOGY (2023)

Article Oncology

Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination

Lieke L. van der Woude, Mark A. J. Gorris, Inge M. N. Wortel, Jeroen H. A. Creemers, Kiek Verrijp, Kim Monkhorst, Katrien Grunberg, Michel M. van den Heuvel, Johannes Textor, Carl G. Figdor, Berber Piet, Willemijn S. M. E. Theelen, I. Jolanda M. de Vries

Summary: This study found that lymphocyte infiltration in the tumor microenvironment is associated with response to therapy in NSCLC patients, regardless of the specific lymphocyte subset. Additionally, the combination of anti-PD-1 and SBRT induced a higher infiltration of cytotoxic T cells compared to anti-PD-1 monotherapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Oncology

Identification of Fusion Genes and Targets for Genetically Matched Therapies in a Large Cohort of Salivary Gland Cancer Patients

Gerben Lassche, Sjoerd van Helvert, Astrid Eijkelenboom, Martijn J. H. Tjan, Erik A. M. Jansen, Patricia H. J. van Cleef, Gerald W. Verhaegh, Eveline J. Kamping, Katrien Grunberg, Adriana C. H. van Engen-van Grunsven, Marjolijn J. L. Ligtenberg, Carla M. L. van Herpen

Summary: This research aimed to assess the prevalence of actionable aberrations in salivary gland cancer (SGC) and identified several new gene fusions. Targets for genetically matched therapies were found in different SGC subtypes. This highlights the potential importance of molecular diagnostics in selecting systemic treatment for SGC.

CANCERS (2022)

Article Oncology

Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non-Small-Cell Lung Cancer in the Netherlands

Henri B. Wolff, Elisabeth M. P. Steeghs, Zakile A. Mfumbilwa, Harry J. M. Groen, Eddy M. Adang, Stefan M. Willems, Katrien Grunberg, Ed Schuuring, Marjolijn J. L. Ligtenberg, Bastiaan B. J. Tops, Veerle M. H. Coupe

Summary: This study evaluates the efficacy of parallel next generation sequencing (NGS)-based testing compared to sequential single-gene-based testing in patients with stage IV nonsquamous non-small-cell lung cancer. The results show that parallel testing is cheaper and more effective than sequential testing, with the ability to detect additional relevant genetic aberrations.

JCO PRECISION ONCOLOGY (2022)

Article Respiratory System

Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden

Guus R. M. van den Heuvel, Leonie I. Kroeze, Marjolijn J. L. Ligtenberg, Katrien Grunberg, Erik A. M. Jansen, Daniel von Rhein, Richarda M. de Voer, Michel M. van den Heuvel

Summary: This study investigated mutational signatures in NSCLC patients using tumor DNA samples, revealing a prominent presence of SBS4 signature in tumors associated with smoking, and SBS2 and/or SBS13 signatures linked to AID/APOBEC enzyme activity. SBS4 signature was significantly more present in early stages of NSCLC, indicating potential clinical significance. Further studies are needed to determine the clinical utility of mutational signature analyses.

RESPIRATORY RESEARCH (2021)

Article Oncology

Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations

Bart Koopman, Harry J. M. Groen, Marjolijn J. L. Ligtenberg, Katrien Grunberg, Kim Monkhorst, Adrianus J. de Langen, Mirjam C. Boelens, Marthe S. Paats, Jan H. von der Thusen, Winand N. M. Dinjens, Nienke Solleveld, Tom van Wezel, Hans Gelderblom, Lizza E. Hendriks, Ernst-Jan M. Speel, Tom E. Theunissen, Leonie I. Kroeze, Niven Mehra, Berber Piet, Anthonie J. van der Wekken, Arja ter Elst, Wim Timens, Stefan M. Willems, Ruud W. J. Meijers, Wendy W. J. de Leng, Anne S. R. van Lindert, Teodora Radonic, Sayed M. S. Hashemi, Danielle A. M. Heideman, Ed Schuuring, Leon C. van Kempen

Summary: This study evaluates the methods and agreement in treatment recommendations among Molecular Tumor Boards (MTBs) from tertiary cancer referral centers in The Netherlands. It found that these MTBs are similar in setup and demonstrate high agreement in recommendations for rare or complex mutational cancer profiles. The proposed Dutch MTB model focuses on collaborative and nationally aligned workflow with interinstitutional collaboration and data sharing.

ONCOLOGIST (2021)

No Data Available